Webinar – Breaking Boundaries:
Accelerating In Vivo CAR-T Antibody Discovery and Development

In vivo CAR-T therapy transforms T cells directly within the body, making treatment faster, simpler, and more accessible, with the potential for repeat dosing and targeting solid tumors. Antibodies guide CAR constructs to tumor-specific antigens, enabling precise T cell activation and proliferation, while supporting multispecific designs that enhance efficacy and reduce off-target effects.

Join ProBio’s webinar to learn how to discover and develop antibodies for in vivo CAR-T applications.

• 

  Derek Chen
  Sr. Director, Antibody Drug Discovery Dept., ProBio

• 

  Ying Li
  Director of Antibody PD Dept., ProBio

Related service: In Vivo CAR-T Discovery, Antibody & Protein CMC Solutions for CGT, LVV Drug Product One-Stop Solution, RNA-tLNP One-Stop Solution

Available materials